Targeting Survivin with Aptamer-siRNA Chimeras for the Treatment of Metastatic Prostate Cancer
Abstract
Prostate cancer is the second leading cause of cancer-related death in the United States. One in 6 men will be diagnosed with prostate cancer during their lifetime, and 1 in 33 men will die of the disease. Locally confined prostate tumors can be effective treated with surgery, radiotherapy, and androgen suppression. However, once tumor cells spread from one organ to another organ, no effective treatments are available, so effective therapies are urgently needed. This proposal will develop new treatment by targeting a key tumor-cause molecule (survivin), which has been proven to support tumor growth and spread. The new approach will use powerful small RNA to delete this tumor trigger, thus it is very likely that the new treatment will bring prostate cancer under the control. This new therapeutic will benefit both new prostate tumor and spread advanced prostate tumors, which have started to attack multiple organs. We envision that patient-related results will take about 3-5 years. The research will bring new therapeutic approach for current incurable advanced prostate cancer patients and offer the hope for prolonged lifespan and quality life for current suffering patients.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Apr 04, 2016
- Source ID
- W81XWH1510333
Entities
People
- Hong Yan Liu
Organizations
- Augusta University
- United States Army